Ligand partner GSK announces record quarterly Promacta™/Revolade™ revenue
Ligand announced that partner GlaxoSmithKline has announced global revenue for Promacta™/Revolade™ for the second quarter ended June 30, 2014 of $92 million, up 31% from the second quarter of 2013. U.S., EU and the Emerging Markets all reported double-digit growth over the prior quarter. July 23, 2014